Mereo BioPharma Group plc · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$0.37
−$0.02 (−5.18%) 4:00 PM ET
After hours$0.37
−$0.00 (−0.25%) 12:30 AM ET
Prev closePrevC$0.39
OpenOpen$0.37
Day highHigh$0.38
Day lowLow$0.36
VolumeVol1,698,948
Avg volAvgVol5,492,050
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$58.97M
Sector
Healthcare
AI report sections
MIXED
MREO
Mereo BioPharma Group plc
Mereo BioPharma’s share price is trading near the low end of its 52-week range after steep 1–6 month declines, with momentum indicators pointing to a market under pressure. Technical signals show persistent downside trend well below key moving averages and within a bearish Keltner and Ichimoku configuration, while short interest and short volume are elevated enough to indicate notable skepticism. The lack of disclosed financial fundamentals in the available data and a predominantly negative recent news backdrop related to legal investigations further underscores a cautious risk profile.
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREO
A securities class action lawsuit has been filed against Mereo BioPharma Group plc (MREO) for allegedly providing misleading statements about Phase 3 clinical trials for setrusumab. The company reportedly made positive statements about the drug's potential while concealing that the ORBIT and COSMIC studies failed to meet their primary endpoints. Investors who purchased ADSs between June 5, 2023 and December 26, 2025 may be eligible for compensation. The lead plaintiff deadline is April 6, 2026.
MREOsecurities class actionclinical trial failuremisleading statementssetrusumabOsteogenesis Imperfectainvestor compensationlead plaintiff deadline
Sentiment note
The company is accused of providing materially misleading statements about clinical trial results, concealing that Phase 3 studies failed to meet primary endpoints while publicly expressing confidence in the drug's success. This deception allegedly caused investors to purchase shares at artificially inflated prices, resulting in significant losses.
NegativeGlobeNewswire Inc.• Rosen Law Firm
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREO
Rosen Law Firm has filed securities class action lawsuits against Mereo BioPharma Group plc, Snowflake Inc., and Masonite International Corporation. The primary case detailed involves Mereo, where defendants allegedly misrepresented Phase 3 clinical trial results for setrusumab, leading investors to purchase shares at artificially inflated prices. The lead plaintiff deadline is April 6, 2026.
MREOSNOWsecurities class actionsecurities fraudclinical trial failureinvestor compensationlead plaintiff deadlinematerial misrepresentation
Sentiment note
Company is accused of providing false and materially misleading statements about Phase 3 clinical trial results for setrusumab, concealing that trials failed to meet primary endpoints. This caused investors to purchase shares at artificially inflated prices, resulting in significant losses.
Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. Investors who purchased Mereo securities between June 5, 2023 and December 26, 2025 are encouraged to join the case, with a lead plaintiff deadline of April 6, 2026.
The company is accused of providing false and misleading statements about clinical trial results while concealing material adverse facts. The Phase 3 ORBIT and COSMIC programs failed to meet primary endpoints, resulting in significant investor losses and a securities fraud class action lawsuit.
NegativeGlobeNewswire Inc.• Rosen Law Firm
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREO
A securities class action lawsuit has been filed against Mereo BioPharma Group plc for allegedly providing misleading statements about Phase 3 clinical trials for setrusumab. The defendants reportedly made positive statements about the drug's potential while concealing that the trials failed to meet their primary endpoints, causing investors to purchase shares at artificially inflated prices. The lead plaintiff deadline is April 6, 2026.
MREOsecurities class actionMereo BioPharmaclinical trial failuresetrusumabmisleading statementsinvestor damageslead plaintiff deadline
Sentiment note
The company is the subject of a securities class action lawsuit alleging material misrepresentation regarding Phase 3 clinical trial results. Defendants allegedly made positive statements about setrusumab while concealing that trials failed to meet primary endpoints, resulting in artificially inflated stock prices and investor losses.
CLASS ACTION ALERTS: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ultragenyx and Mereo BioPharma and Encourages Investors to Contact the Firm
Class action lawsuits have been filed against Ultragenyx Pharmaceutical and Mereo BioPharma for allegedly misleading investors about Phase III clinical trial results for setrusumab in treating Osteogenesis Imperfecta. Both companies announced on December 29, 2025, that their ORBIT and COSMIC studies failed to meet primary endpoints for reducing annualized fracture rates. Ultragenyx stock fell 42.32% and Mereo's ADS declined 87.7% following the announcements. Lead plaintiff deadlines are set for April 6, 2026.
Company faces class action lawsuit for concealing adverse facts about Phase III trial results. Stock experienced severe decline of 87.7% after announcing ORBIT and COSMIC studies failed to meet primary endpoints for reducing annualized fracture rates.
Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. Investors who purchased Mereo securities between June 5, 2023 and December 26, 2025 are eligible to join the lawsuit, with a lead plaintiff deadline of April 6, 2026.
The company is accused of providing false and misleading statements about clinical trial results while concealing material adverse facts. The failure of Phase 3 ORBIT and COSMIC programs to meet primary endpoints represents significant setbacks for the company's pipeline and investor confidence.
NegativeGlobeNewswire Inc.• Rosen Law Firm
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREO
Rosen Law Firm has filed a securities class action lawsuit against Mereo BioPharma Group plc on behalf of investors who purchased American Depositary Shares between June 5, 2023 and December 26, 2025. The lawsuit alleges that defendants made false and misleading statements about Phase 3 clinical trials (Orbit and COSMIC studies) for setrusumab, claiming confidence in the drug's ability to reduce fracture rates while concealing that neither study met its primary endpoints. Investors who purchased during this period at artificially inflated prices may be entitled to compensation. The deadline to serve as lead plaintiff is April 6, 2026.
MREOsecurities class actionclinical trial failuremisleading statementssetrusumabOsteogenesis Imperfectainvestor compensationlead plaintiff deadline
Sentiment note
The company is accused of providing materially misleading statements about clinical trial results, concealing that Phase 3 studies failed to meet primary endpoints while publicly expressing confidence in the drug's success. This deception allegedly caused investors to purchase shares at artificially inflated prices, resulting in significant losses.
NegativeGlobeNewswire Inc.• Rosen Law Firm
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREO
Rosen Law Firm has filed a class action lawsuit against Mereo BioPharma Group plc on behalf of investors who purchased American Depositary Shares between June 5, 2023 and December 26, 2025. The lawsuit alleges that defendants made false and misleading statements about Phase 3 clinical trials (Orbit and COSMIC studies) for setrusumab, claiming confidence in the drug's ability to reduce fracture rates while concealing that neither study met its primary endpoints. Investors who purchased during this period at artificially inflated prices may be entitled to compensation. The lead plaintiff deadline is April 6, 2026.
MREOsecurities class actionclinical trial failuremisleading statementssetrusumabOsteogenesis ImperfectaPhase 3 trialsinvestor compensation
Sentiment note
The company is the defendant in a securities class action lawsuit alleging material misrepresentation regarding clinical trial results. Defendants allegedly made positive statements about drug efficacy while concealing that Phase 3 trials failed to meet primary endpoints, causing investors to purchase shares at artificially inflated prices. This represents significant legal and reputational risk.
Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. Investors who purchased Mereo securities between June 5, 2023 and December 26, 2025 are encouraged to join the case, with a lead plaintiff deadline of April 6, 2026.
The company is accused of providing false and misleading statements about clinical trial results while concealing material adverse facts. The Phase 3 ORBIT and COSMIC programs failed to meet primary endpoints, resulting in significant investor losses and a securities fraud class action lawsuit.
NegativeGlobeNewswire Inc.• Levi & Korsinsky, Llp
Levi & Korsinsky Notifies CoreWeave, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – CRWV
Law firm Levi & Korsinsky has filed class action securities lawsuits against CoreWeave, Inc., Mereo BioPharma Group plc, and Richtech Robotics Inc. CoreWeave investors who suffered losses between March 28, 2025 and December 15, 2025 can claim compensation by March 13, 2026. The complaint alleges CoreWeave overstated its ability to meet customer demand and understated risks from reliance on a single third-party data center supplier, resulting in materially false public statements.
Company is subject to a class action securities lawsuit with investors required to contact counsel by April 6, 2026, indicating alleged securities violations and investor losses.
NegativeGlobeNewswire Inc.• Levi & Korsinsky, Llp
Klarna Group plc Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 20, 2026 to Discuss Your Rights – KLAR
Levi & Korsinsky, LLP has filed a class action securities lawsuit against Klarna Group plc, alleging that defendants made false statements and concealed material risks regarding loss reserves that increased significantly after the company's September 2025 IPO. Investors who purchased Klarna securities have until February 20, 2026 to request lead plaintiff status. The lawsuit also mentions pending cases against Mereo BioPharma Group plc and Richtech Robotics Inc.
The company is subject to a pending class action securities lawsuit, indicating alleged securities violations and investor losses, though specific details are not provided in the article.
NegativeGlobeNewswire Inc.• Levi & Korsinsky, Llp
Class Action Filed Against Beyond Meat, Inc. (BYND) Seeking Recovery for Investors – Contact Levi & Korsinsky
Levi & Korsinsky has filed class action securities lawsuits against Beyond Meat, Mereo BioPharma Group, and Richtech Robotics on behalf of investors who suffered losses due to alleged securities fraud. Beyond Meat is accused of concealing material asset impairment charges and making false statements between February 27, 2025 and November 11, 2025. Investors have until specified deadlines to request lead plaintiff status.
Company is subject to a class action securities lawsuit filed by Levi & Korsinsky, indicating alleged securities violations and investor losses.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
